01 — Characterise
The active first: solubility, stability, polymorphism, incompatibilities. Most formulation failures are traceable to something skipped here.
Pillar 01
Formulatin.
A molecule that works in a flask is not yet a product. Formulation is the discipline that carries it the rest of the way.
The discipline
Stability, absorption and manufacturability are one problem
They are usually treated as three, solved in sequence by three different groups. The result is familiar: a formulation with excellent dissolution that degrades in month four, or a stable one that no production line can reproduce at scale.
We work the three together from the start. Characterise the active and what attacks it. Choose a matrix that protects it without impeding release. Check at every step that the thing can still be made in the quantity intended, on equipment that exists. It is slower at the beginning and considerably faster overall.
We work across both pharmaceutical and nutraceutical products, and treat the distinction between them as regulatory rather than scientific. A nutraceutical active obeys the same physical chemistry as a drug substance; the evidentiary burden differs, the rigour should not.
Capability
What we do
Engagements range from a single defined technical question to development of a formulation from the active outwards. In either case the deliverable is the same in kind: a documented result with its limits stated.
- Formulation development — solid, semi-solid and liquid oral forms, from first principles or an existing brief.
- Excipient and matrix design — selecting the system that carries the active without fighting it.
- Stability and shelf-life — degradation pathways identified early, not discovered late.
- Bioavailability strategy — solubility and release profile treated as design targets, not outcomes.
- Scale-up readiness — formulations designed to survive the move from bench to batch.
- Analytical method development — because a formulation is only as good as the method that verifies it.
- Reformulation and rescue — diagnosing why an existing formulation underperforms, and correcting it.
Method
How a formulation programme runs
02 — Design
Matrix and excipient system chosen against explicit targets for release, stability and manufacturability, with the trade-offs written down.
03 — Verify
Analytical methods developed alongside the formulation, so that every claim about it has a method capable of testing that claim.
04 — Transfer
Documentation and process understanding handed over in a form a manufacturing site can act on without reinterpretation.
Formulation that has stalled?
Bring the problem and the data behind it. Technical conversations proceed under confidentiality as a matter of course.